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Abstract The Fc portion of immunoglobulin G (IgG) expresses
paired oligosaccharides with microheterogeneities, which are
associated with efficiencies of effector functions and with
pathological states. A comparison of electrospray ionization
mass spectrometry data obtained using a variety of Fc fragments
derived from human and mouse IgG that do and do not retain the
inter-chain disulfide bridge(s) revealed that (1) the Fc portion can
be asymmetric as well as symmetric with respect to glycosylation
and (2) the ratios of the individual glycoforms are different from
what is expected from the random pairing.
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1. Introduction
Immunoglobulin G (IgG), which is a multifunctional glyco-
protein with an approximate molecular mass of 150 kDa,
consists of two heavy chains (with identical amino acid se-
quences) and two light chains (with identical amino acid se-
quences). The heavy chains are composed of four homologous
domains, VH, CH1, CH2 and CH3, whereas the light chains are
divided into two homologous domains, VL and CL. The CH1
and CH2 domains are separated by the hinge region, where
the two heavy chains are disul¢de-linked to each other. The
hinge region is generally susceptible to the attack of proteases,
e.g. papain, giving rise to the Fab and the Fc fragments. The
Fab portions carry antigen recognition, whereas the Fc por-
tion promotes a variety of e¡ector functions.
IgG molecules possess one conserved glycosylation site at
Asn-2971 in the CH2 domain of each of the heavy chains,
where complex biantennary type oligosaccharides are ex-
pressed (Fig. 1). It has been reported that aglycosyl IgG mol-
ecules, which have been prepared by treating hybridoma cells
with tunicamycin or by site-directed mutagenesis at position
297, retain little ability in activating complements and in bind-
ing to FcQ receptors (FcQR) [1,2]. These results indicate that
the oligosaccharide linked to Asn-297 is essential for the ex-
pression of the proper e¡ector functions of IgG.
It is widely known that the carbohydrate chains exhibit
various microheterogeneities resulting from the presence or
absence of fucose (Fuc), bisecting N-acetylglucosamine
(GlcNAc), galactose (Gal) and sialic acid, e.g. N-acetylneur-
aminic acid (NeuAc) residues (Fig. 1), depending on species,
aging, pathological states and culture conditions of IgG-pro-
ducing cells (for review, see [3^5]). In the case of mouse IgG
antibodies, the N-linked oligosaccharides lack bisecting
GlcNAc and are almost fully fucosylated [6].
The neutral oligosaccharides linked to IgG are classi¢ed
into three types, i.e. G0, G1 and G2, which possess zero,
one and two terminal Gal residues, respectively. The propor-
tion of carbohydrate chains of IgG bearing G0 is increased in
sera of patients with rheumatoid arthritis (RA) [7,8], juvenile
chronic arthritis [9] active Crohn’s disease [10,11], infection
due to Mycobacterium tuberculosis [11] or spondyloarthropa-
thy [12]. The decrease in the galactosylation of IgG oligosac-
charides has also been found in autoimmune MRL/Mp-lpr/lpr
mice [13]. It has been reported that agalactosyl IgG glyco-
forms are directly associated with pathogenicity in murine
collagen-induced arthritis [14]. Certain rheumatoid factors
(RFs) bind better to IgG that is de¢cient in Gal [15]. It has
been recently proposed that agalactosyl IgG activates comple-
ments through interaction with mannose-binding protein
(MBP), an endogenous lectin, resulting in the in£ammation
of RA [16]. By contrast, Gal content in IgG carbohydrate
chains is signi¢cantly increased during pregnancy, when re-
mission of RA symptoms occurs [17]. In addition, galactosy-
lation of fetal IgG is higher than that of maternal IgG, which
suggests that there exists a placental selective transport with
preference for highly galactosylated IgG molecules [18,19].
It has been reported that agalactosyl IgG exhibits a signi¢-
cant degree of reduction of the ability to bind to complement
component C1q and FcQRs resulting in impaired e¡ector
functions [10^23] and slower clearance of this molecule [24].
Although the observed e¡ects of agalactosylation on FcQR-
mediated activity varies depending upon details of the analy-
ses, and even contradictory data have been reported [25^28],
the hypothesis that di¡erent glycoforms of IgG have di¡erent
roles in vivo is worth addressing.
A variety of techniques have been used to obtain informa-
tion concerning the glycoforms of IgG-Fc. The levels of ga-
lactosylation of IgG have been conventionally estimated by
membrane blots and by enzyme-linked immunosorbent assay
(ELISA)-based assays using lectins or anti-GlcNAc antibodies
(for reviews, see [29,30]). Chromatographic methods have
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greatly facilitated the determination of prevalence of oligosac-
charides released from IgG [31]. Especially the high-perform-
ance liquid chromatography (HPLC) analyses of pyridylami-
no derivatives of oligosaccharides have made it possible to
identify individual neutral and sialyl oligosaccharides rapidly
[32^34]. Recently, electrospray ionization (ESI) and matrix-
assisted laser desorption/ionization (MALDI) have greatly ex-
panded the analytical utility of mass spectrometry (MS) for
the structural characterization of biological macromolecules
including IgG and its proteolytic fragments [35,36]. Informa-
tion of carbohydrate heterogeneity has been provided by ESI-
MS analyses of digested peptides [37^39], monomeric Fc sub-
units [40^43] or reduced heavy chains of IgG [37,41,44,45].
Although all of the above techniques have contributed
greatly to the elucidation of IgG glycosylation pro¢les, an
incidence of G0 determined by chemical sequencing does
not always correlate with the level of agalactosyl IgG (IgG
with no Gal residue) estimated by an ELISA-based assay us-
ing an anti-GlcNAc antibody [46]. As an explanation for this
paradox, Williams and Rademacher have suggested that se-
lective pairing of agalactosyl oligosaccharides in one IgG mol-
ecule is necessary for epitope formation and therefore enhan-
ces the binding to the anti-GlcNAc antibodies. Similar
concepts can be applicable in considering the interactions of
IgG with other ligands. Namely, it is possible that particular
pairing of oligosaccharides is necessary for optimum binding
of IgG to C1q, FcQRs, RFs and/or MBP, and the apparent
contradiction among the data so far reported on the glyco-
form^function relationships of IgG is, at least partially, due to
the lack of information of the mode of pairing of the oligo-
saccharides. White et al. have reported that a pair of dinitro-
phenyl-speci¢c murine monoclonal IgG2a having similar
monosaccharide content show di¡erence in lectin-binding
and complement activation [47]. Although the authors have
suggested that orientation of the N-glycan is di¡erent between
these antibodies resulting in di¡erential abilities of lectin-bind-
ing and of interaction with the complement system, it is pos-
sible that the observed di¡erences are due to the di¡erence in
incidence of pairing of particular oligosaccharides. Therefore,
knowledge concerning pairing of oligosaccharides in Fc is of
vital importance for our further understanding of biological
and pathological signi¢cance of the heterogeneities of the IgG
glycans.
Since two oligosaccharides are paired in the Fc region of
one IgG molecule, complete glycoforms of IgG-Fc can be
quite diverse. For example, the 16 kinds of neutral oligosac-
charides, which have been identi¢ed in human IgGs, theoret-
ically give rise to 136 glycoforms. X-ray crystallographic stud-
ies have shown that the pair of carbohydrate chains are
packed between the two CH2 domains: the core and
ManK1-6 branch make contact with an inner surface of the
CH2 domain, whereas the ManK1-3 branch protrudes to the
space between the CH2 domains [48^51]. In the crystal struc-
ture of the rabbit IgG-Fc, the terminal Gal residue of the
ManK1-3 branch of one sugar chain makes contact with the
ManK1-3 branch of the opposing sugar chain, leaving no
space to accommodate the two galactosylated ManK1-3
branches [3,49]. On inspection of this observation, it has
been proposed that one of the paired oligosaccharides must
always devoid Gal in the ManK1-3 branch, i.e. not all possible
Fig. 1. Structure of the fully matured complex biantennary type oligosaccharide (top) and 16 possible structures of neutral oligosaccharide con-
tained in IgG-Fc (A^P). Key: F, fucose; G, galactose; GN, N-acetylglucosamine; M, mannose.
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combination of the carbohydrate chains can occur. Since no
experimental methodology that could determine oligosaccha-
ride pairing in Fc has so far been established, the upper and
lower estimates of IgG glycoform population have been com-
puted on the basis of molar percentage of oligosaccharides
liberated from IgG, postulating the pairing rules [52].
Mass spectrometry has a potential ability to elucidate pair-
ing of oligosaccharides in IgG-Fc. Previous studies have
shown that ESI-MS spectra of IgG and Fc fragments, which
retain the inter-chain disul¢de bridge, exhibit multiple series
of peaks that are associated with the carbohydrate heteroge-
neities [41,44,45]. However, in these studies, identi¢cation of
the unambiguous glycoforms of Fc has never been achieved
mainly due to the lack of information of glycan structures
with discrimination of isomeric carbohydrate moieties. Also,
it has never been clari¢ed whether the MS data thus obtained
could provide quantitative information of IgG glycoforms.
Here, we performed structural analyses of IgG glycoforms
by combined use of the HPLC and ESI-MS methods. The
structure and prevalence of oligosaccharides contained in
the Fc fragments of IgG used were unambiguously determined
by HPLC analyses on their pyridylamino derivatives. It was
demonstrated that Fc glycosylation pro¢les estimated by nano
ESI-MS are in agreement in a quantitative way with those
obtained by the HPLC analyses of the liberated oligosaccha-
rides. By use of the Fc fragment retaining inter-chain disul¢de
bridge(s), pairing of oligosaccharides in Fc has been analyzed.
2. Materials and methods
2.1. Puri¢cation of IgGs
Mouse monoclonal IgG antibodies were prepared by cultivating
IgG-producing cells. Cell lines 27-13.6 and 27-35.8, which produce
mouse anti-dansyl IgG2a and IgG2b, respectively [39,53], were gen-
erously provided by Professor L.A. Herzenberg and Dr. V.T. Oi, and
adopted to a serum-free medium (Nissui NYSF 404). The IgG-pro-
ducing cells were cultivated in tissue culture £asks (Corning) at 37‡C
in a humidi¢ed atmosphere of 5% CO2/95% air. After cell growth,
mouse IgGs were isolated from the supernatants by use of an A⁄-Gel
protein A column (Bio-Rad) as described previously [54].
Human IgG was isolated from venous samples collected from preg-
nant women or from the umbilical cord (fetus) by use of protein G
a⁄nity columns as described previously [19]. For desialylation, 20 mU
of sialidase from Arthrobacter ureafaciens (Nacalai Tesque) was used
to treat 500 pmol of substrate in 15 Wl of 0.1 M citrate-phosphate
bu¡er, pH 5.0, at 37‡C for 16 h.
2.2. Preparation of Fc fragments
Fc fragments retaining the inter-chain disul¢de bridge(s) were pre-
pared by proteolysis as described with slight modi¢cations [55,56].
The mouse IgG (10 mg/ml) was incubated in the presence of Lys-C
endoprotease (Wako Pure Chemical Industries) at pH 8.5, 37‡C in
50 mM Tris^HCl for 1 h. The enzyme/substrate molar ratio was
1:200. The reaction was terminated by the addition of 3 mM diiso-
propyl £uorophosphate. The human IgG (0.5^5 mg/ml) was incubated
in the presence of papain (Sigma) at 37‡C, in 75 mM sodium phos-
phate bu¡er, pH 7.0, containing 75 mM NaCl and 2 mM EDTA for
4.5^6 h. The enzyme/substrate molar ratio was 1:25. The reaction was
terminated by the addition of 33 mM N-ethylmaleimide. The Fc frag-
ments were puri¢ed by a combined use of protein A a⁄nity chroma-
tography and Superose 12 gel-¢ltration HPLC (Amersham Pharmacia
Biotech) as described [56]. By amino acid sequence analyses on an
Applied Biosystem protein sequenator model 477A/120A, the N-ter-
minal residues of the Fc fragments of mouse IgG2a, IgG2b and hu-
man IgG1 was con¢rmed as Lys-228, 228D and Thr-225, respectively.
The Fc fragments (1^5 mg/ml) were reduced by 10 mM DTT at
room temperature for 1 h in 1.5 M Tris^HCl, pH 8.5, containing
Fig. 2. Glycosylation pro¢les of Fc/2 fragment of mouse IgG2b:
raw (a) and transformed (b) nano ESI-MS spectra of Fc/2 and an
HPLC pro¢le of pyridylamino derivatives of N-linked oligosaccha-
rides liberated from Fc/2 on an ODS column (c). The alphabetical
peak codes correspond to those of the oligosaccharide structures in
Fig. 1. In (b), F* represents either F or G (see text). The structure
of oligosaccharide Q is shown in (c). Peaks EP and FP in (c) are due
to epimers of the pyridylamino derivatives corresponding to peaks
E and F, respectively. The two very minor peaks observed at
26472.8 and 26634.9 Da were tentatively assigned to (Fuc)-
(Hex)4(HexNAc)4(NeuGc) and (Fuc)(Hex)5(HexNAc)4(NeuGc), re-
spectively, although these monosialyl glycoforms were barely de-
tected in the HPLC analysis because of a low incidence (less than
1%).
C
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2 mM EDTA. For alkylation, 22 mM iodoacetic acid was added to
the reaction mixture, which was incubated in the dark for 20 min at
room temperature. The reaction was stopped by addition of 10 mM
DTT and then dialyzed against water. Hereafter, the Fc fragment
retaining the inter-chain disul¢de bridge(s) and the reduced and alky-
lated Fc fragment, which is detected as monomeric subunit in ESI-
MS, will be simply designated as Fc and Fc/2, respectively.
2.3. Nano£ow ESI-MS analyses
Nano ESI-MS was acquired using a Q-TOF instrument (Micro-
mass, Manchester, UK) and MassLynx data acquisition. This instru-
ment is a hybrid quadrupole orthogonal acceleration time-of-£ight
mass spectrometer, with a Z-spray nano£ow electrospray ion source.
The mass spectrometer was operated in the positive-ion mode. Reso-
lution of the mass spectrometer was 5000 at m/z 1500. The cone
voltage was set to 50^70 V. Puri¢ed samples were extensively dialyzed
against water, lyophilized and then dissolved at a protein concentra-
tion of 1^20 WM in a solution containing equal amounts of acetoni-
trile and 0.2% formic acid. Two Wl of the sample solution was loaded
into a nano£ow tip. A £ow rate of about 50 nl/min into the analyzer
was produced as a result of a potential of 1.0 kV applied to the
nano£ow tip in the ion source. Ten to 20 spectra were averaged,
baseline subtracted, smoothed, centroided and deconvoluted.
2.4. HPLC analyses of oligosaccharide pro¢le
Neutral and sialyl oligosaccharide analyses of IgG were performed
by HPLC, as previously described in detail [32^34]. The oligosaccha-
ride moieties were released by enzymatic cleavage with glycoamidase
A (Seikagaku Kogyo). The reducing ends of the oligosaccharides were
reductively aminated with 2-aminopyridine by use of sodium cyano-
borohydride [57]. The mixture of pyridylamino derivatives of the ol-
igosaccharides thus obtained was applied onto a diethylaminoethyl
(DEAE) HPLC column to separate neutral, monosialyl and disialyl
oligosaccharide fractions, each of which was then subjected to HPLC
analysis on a Shim-pack CLC-octadecylsilyl (ODS) column (Shimad-
zu) with £uorescence detection. The collected fraction was further
subjected to an HPLC analysis using a TSK-GEL Amide-80 column
(Tosoh) if necessary. The structure of each peak separated on the
column was identi¢ed as described previously [32^34].
3. Results and discussion
3.1. Oligosaccharide pro¢les by ESI-MS
For obtaining information of the Fc-associated glycoforms
by MS, the use of Fc fragments was essential, because the
resolution of ESI-MS of intact IgG was not su⁄cient for
quantitative analyses [41,44,45]. It is also possible that glyco-
sylation in the Fab and/or the hinge regions can make the
spectral analyses equivocal. We have established protocols
to prepare Fc as well as Fc/2 fragments of mouse IgG2a,
IgG2b and human IgG1 with the homogeneous N-terminal
[55,56]. Firstly, by using the Fc/2 fragments, we compared
glycosylation pro¢les obtained by nano ESI-MS with those
determined by HPLC analyses of the liberated oligosaccha-
rides.
Fig. 2a,b show nano ESI-MS and its transformed spectra of
the Fc/2 fragment of a mouse IgG2b antibody. Two major
(25999.5 and 26161.6 Da) and two minor (25796.3 and
26323.8 Da) ion peaks are observed in the spectra with
mass di¡erences corresponding to a hexose or N-acetylhexos-
amine residue. Molecular mass of the polypeptide chain of
this Fc/2 calculated on the basis of the amino acid sequence
[39] is 24555.9. This led us to conclude that the chemical
structures of glycans corresponding to the observed ion peaks
Table 1
Major glycoforms of Fc/2 fragments
Fc/2 Glycoforms Molecular mass (Da) Relative quantity
calculated observed ESI-MSa HPLCb
Mouse IgG2b (lot 1)c Q 25798.1 25796.3 6.2 8.1
E 26001.3 25999.5 45.7 47.9
F* 26163.4 26161.6 40.1 37.8 (30.5)g
H 26325.6 26323.8 8.0 6.2
Mouse IgG2b (lot 2) E 26001.3 26000.7 15.6 14.8
F* 26163.4 26163.0 57.4 56.7 (50.4)
H 26325.6 26325.2 27.0 28.5
Mouse IgG2a (lot 1) E 26380.8 26382.1 41.7 39.4
F* 26543.0 26543.8 52.8 56.4 (53.7)
H 26705.1 26706.3 5.5 4.2
Mouse IgG2a (lot 2) E 26380.8 26380.7 54.2 52.8
F* 26543.0 26543.1 44.1 44.8 (41.0)
H 26705.1 26705.7 1.7 2.4
Maternal human IgG1d E 26495.8 26494.9 8.1 8.5
F* 26657.9 26657.1 31.6 28.7 (25.8)
H 26820.1 26819.2 60.3 62.8
Fetal human IgG1e E 26495.8 26493.9 8.8 10.3
F* 26657.9 26656.3 22.9 24.6 (22.0)
H 26820.1 26818.3 43.8 46.6
Mcf 27111.3 27109.6 24.5 18.5
aRelative ion intensities in transformed spectrum.
bRelative peak areas.
cESI-MS spectrum is shown in Fig. 2.
dWith sialidase treatment.
eESI-MS spectrum is shown in Fig. 3.
f Structure of Mc:
gRelative quantities of F are indicated in parentheses.
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at 25796.3, 25999.5, 26161.6 and 26323.8 Da are (Fuc)(Hex)3-
(HexNAc)3, (Fuc)(Hex)3(HexNAc)4, (Fuc)(Hex)4(HexNAc)4
and (Fuc)(Hex)5(HexNAc)4, respectively. Fig. 2c shows the
HPLC elution pro¢les of the pyridylamino derivatives of the
oligosaccharides released from the same Fc/2 fragment used in
the experiment. The oligosaccharides attached to the IgG2b-
Fc used consist of two major components, E and F, and three
minor components, G, H and Q. No sialyl oligosaccharides
were detected for the Fc sample (data not shown). Oligosac-
charide Q is monoantennary and lacks GlcNAc linked to the
ManK1-6 residue. Monoantennary oligosaccharides have been
detected in human IgG2 and IgG3 paraproteins [5] and hu-
man IgG1 and IgG2 secreted by human^mouse hybridoma
[58]. As far as we know, this is the ¢rst example of a mono-
antennary oligosaccharide detected in mouse IgG.
On the basis of these data, we assigned the ESI-MS ion
peaks to Q, E, F plus G, and H as indicated in Fig. 2b.
Although oligosaccharides F and G are isomeric with each
other and, therefore, cannot be distinguished solely on the
basis of the ESI-MS data, the HPLC pro¢le clearly indicates
that F predominates G (Fig. 2c). Hereafter, an oligosaccha-
ride that can be either F or G will be represented as F*. It
should be noted that the relative intensities of the nano ESI-
MS ion peaks are in good agreement with those of the corre-
sponding neutral oligosaccharides detected in the HPLC pro-
¢le.
We have also compared the glycosylation pro¢les obtained
by nano ESI-MS with those determined on the basis of the
HPLC elution pro¢les for Fc/2 fragments of various samples
of mouse and human IgG antibodies, which contain only
neutral oligosaccharides with di¡erent degrees of galactosyla-
tion. The results are summarized in Table 1. In each case,
relative quantities of individual glycans determined by the
nano ESI-MS analyses are in good agreement with those de-
termined by the HPLC analyses.
We have further examined the glycoforms of the Fc/2 frag-
ment of fetal human IgG1 by nano ESI-MS as well as HPLC
methods (Fig. 3). As shown in Fig. 3b, the Fc/2 fragment of
the fetal human IgG1 used is heavily galactosylated and con-
tains NeuAc exclusively at the terminal of ManK1-3 branch.
Preferential monosialylation on the ManK1-3 branch has been
commonly observed for IgG-Fc [59]. Although the spectrum is
complicated owing to the minor peaks from bisected or sialyl
glycoforms, the relative intensities of the major ion peaks
Fig. 3. Glycosylation pro¢les of Fc/2 fragment of human IgG1: raw (a) and transformed (b) nano ESI-MS spectra of Fc/2 and an HPLC pro-
¢le of pyridylamino derivatives of N-linked oligosaccharides liberated from Fc/2 (c). In (c), elution pro¢les on an ODS column of pyridylamino
derivatives of neutral and monosialyl oligosaccharides, which were previously separated on a DEAE column, are individually shown. Virtually
no disialyl oligosaccharide was detected for the Fc/2 sample (data not shown). The structure of oligosaccharide Ma is shown in (c), where S
represents N-acetylneuraminic acid. Peaks EP, FP and HP in (c) are due to epimers of the pyridylamino derivatives corresponding to peaks E, F
and H, respectively. The minor peaks observed at 26858.9, 26963.2, 27020.8 and 27401.1 Da are due to N and/or O, Ma, P and disialyl glyco-
forms, respectively.
FEBS 23687 11-5-00
K. Masuda et al./FEBS Letters 473 (2000) 349^357 353
again well correlate with those of corresponding peaks in the
HPLC elution pro¢les. On the basis of all of these data, we
conclude that nano ESI-MS provides us with information of
glycoforms of IgG-Fc involving neutral and sialyl oligosac-
charides in a quantitative way.
Roberts et al. have shown that MALDI- and ESI-MS data
of tryptic glycosylated non-apeptides originating from a re-
shaped human monoclonal IgG provide us with quantitative
information on the carbohydrate chains [38]. They have ar-
gued that di¡erences in charging of glycans in ESI-MS can
a¡ect the observed ion peak ratios among glycoforms and the
lowest charge state re£ect the relative solution concentrations
most faithfully. In the present data, a modest di¡erence in ion
peak ratios was observed for di¡erent charge states (Figs. 2a
and 3a), indicating that any e¡ects resulting from the charging
of glycans on apparent prevalence of individual glycoforms
are negligible for larger glycoproteins such as Fc/2 as com-
pared with small glycopeptides.
3.2. Pairing of the carbohydrate chains in Fc
In order to obtain information of pairing of oligosaccha-
rides in the Fc region, Fc fragments, which retain the inter-
chain disul¢de bridge(s) in the hinge region, were subjected to
mass spectrometry. Fig. 4a,b show nano ESI-MS spectrum of
the Fc fragment of mouse IgG2b with the inter-chain disul¢de
bridge, which is the counterpart of the Fc/2 fragment shown
in Fig. 2. In the transformed ESI-MS spectrum, ion peaks
corresponding to the individual pairing were clearly observed
showing that glycoforms with homologous (e.g. Q+Q and
E+E) and heterologous (e.g. Q+E and E+F*) combinations
of oligosaccharides co-exist. Ratios of individual glycoforms
are shown in Table 2. It should be noted that the ratios of the
individual glycoforms were signi¢cantly di¡erent from what is
expected on the basis of the random pairing. Namely, pairing
of the carbohydrate moieties tends to be homologous with the
exception that the incidence of the F*+H pairing surpasses the
expectation. For example, the incidence of the E+F* pairing,
which would be protuberant if a random pairing is assumed,
is just comparable with those of E+E and F*+F*. A similar
tendency was observed for mouse IgG2a-Fc (Table 2).
It is possible that the glycosylation pro¢les that involve
pairing of the oligosaccharides in Fc o¡er insights into intra-
cellular tra⁄cking of individual IgG molecules on the biosyn-
thesis pathway. The high mannose (Man) carbohydrate moi-
eties containing three glucose (Glc) residues (Glc3Man9-
GlcNAc2) is transferred from dolichyldiphosphate to Asn-
297 in a newly synthesized IgG heavy chain polypeptide as
it emerges from the ribosome. After removal of the three
terminal Glc, the glycoprotein moves to the Golgi, where
the two heavy and two light chains have been already as-
sembled [60] and enzymes involved in processing of glycan
are compartmentalized [61]. In the cis Golgi, the glycans
undergo trimming of the Man residues by K-mannosidases.
Next, in the medial Golgi, the glycans are further trimmed
and fucosylated giving rise to oligosaccharide Q and then
converted to oligosaccharide E by N-acetylglucosaminyltrans-
Fig. 4. Glycosylation pro¢les of Fc fragments of mouse IgG2b (a, b) and fetal human IgG1 (c, d): raw (a, c) and transformed (b, d) nano
ESI-MS spectra of the Fc fragments. In (d), each peak exhibits a shoulder presumably due to a sodium adduct.
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ferase II (GnT-II). The glycoprotein then moves to the trans
Golgi, where it undergoes galactosylation by L1,4 galactosyl-
transferase (L1,4-GTase) and sialylation by K2,6 sialyltransfer-
ase. The present nano ESI-MS data revealed that oligosaccha-
ride Q is paired either with Q itself or E but not with
galactosylated oligosaccharides, i.e. F* and H. This indicates
that the IgG molecules carrying oligosaccharide Q, which is
generated possibly as a result of de¢ciency of GnT-II in the
medial Golgi, escape galactosylation in the trans Golgi. Var-
ious possibilities may explain the observed bias: (1) there ex-
ists a bypass from the medial Golgi that allows IgG to be
secreted without moving to the trans Golgi, (2) oligosaccha-
ride Q in one heavy chain precludes galactosylation of oligo-
saccharide E in the other heavy chain in the same IgG mol-
ecule and (3) a subset of hybridoma is de¢cient in L1,4-GTase
as well as in GnT-II.
The present nano ESI-MS data also showed that oligosac-
charide H is predominantly paired with F*, resulting in low
incidences of the pairing H+H and E+H. Namely, selective
digalactosylation of one of two heavy chains (giving rise to
the G0+G2 pairing) or digalactosylation in both of the heavy
chains (giving rise to the G2+G2 pairing) seldom occurred in
the cells. The quite low incidence of the G2+G2 pairing seems
to be consistent with the pairing rule proposed on the basis of
the X-ray crystallographic data of rabbit IgG-Fc [3,49]. How-
ever, it has been reported that G2 contributes 62% of oligo-
saccharides of human IgG4 paraprotein A.S. [5]. This would
indicate that at least 24% of IgG possesses the G2 type oli-
gosaccharide moieties on both Fc subunits unless non-glyco-
sylated Fc subunits exist. A high percentage of G2 oligosac-
charides (around 75%) has been also reported for human
monoclonal IgG2 produced by Epstein-Barr virus-trans-
formed B-lymphoblastoid cell lines grown in serum-free me-
dium in low density static cultures [21]. In order to address
this issue more directly, we examined the pairing of the Fc
fragment of fetal human IgG1, which is more heavily galac-
tosylated and sialylated than the mouse IgGs used in the
present study.
The nano ESI-MS spectrum of the Fc fragment of fetal
human IgG1 with the inter-chain disul¢de bridges, which is
the counterpart of the Fc/2 fragment shown in Fig. 3, indi-
cates that there absolutely exists a signi¢cant amount of the
Fc molecules that exhibit the H+H pairing (Fig. 4c,d and
Table 2). As far as we know, this is the ¢rst direct evidence
for the existence of the G2+G2 pairing in IgG that occurs
naturally. The present ESI-MS data indicate that the pairing
rule is not so strict, if any. It is likely that the low incidence of
the H+H pairing observed for the mouse IgG2b-Fc is presum-
ably due to a low concentration of L1,4-GTase in the cells,
which is not su⁄cient to achieve galactosylation of every po-
tential substrate.
Furthermore, the present ESI-MS data clearly indicates the
existence of the IgG molecules exhibiting the Mc+Mc pairing.
Although little is known about the biological signi¢cance of
the sialylation of IgG-Fc, it has been suggested that NeuAc
residues occupy space in the vicinity of His residues involved
in binding to the neonatal Fc receptor (FcRn), which is ex-
pressed on many tissues and involved in the control of trans-
port and the catabolism of IgG, and can in£uence their pKa
values [62]. Since the stoichiometry of the interaction between
Table 2
Major glycoforms of Fc fragments
Fc Glycoforms Molecular mass (Da) Relative quantity
calculated observed calculateda observedb
Mouse IgG2b (lot 1) Q+Q 51478.1 51479.4 0.4 3.9
Q+E 51681.3 51679.0 5.7 5.3
Q+F* 51843.4 ndc 5.0 nd
E+E 51884.5 51882.8 20.9 28.3
Q+H 52005.6 nd 1.0 nd
E+F* 52046.6 52045.0 36.7 27.9
F*+F* 52208.8 52207.1 16.0 21.6d
E+H 52208.8 52207.1 7.3 2.1d
F*+H 52370.9 52368.8 6.4 9.1
H+H 52533.0 52530.6 0.6 1.8
Mouse IgG2a (lot 1) E+E 52643.5 52644.6 17.4 22.2
E+F* 52805.7 52807.2 44.0 34.3
F*+F* 52967.8 52969.7 27.9 31.9d
E+H 52967.8 52969.7 4.6 4.1d
F*+H 53130.0 53129.3 5.8 7.5
H+H 53292.1 nd 0.3 nd
Fetal human IgG1 E+E 52755.4 52757.6 0.8 4.9
E+F* 52917.5 52918.4 4.0 5.3
F*+F* 53079.7 53081.4 5.3 7.4d
E+H 53079.7 53081.4 7.7 2.1d
F*+H 53241.8 53246.1 20.0 18.2
E+Mc 53370.9 nd 4.3 nd
H+H 53404.0 53405.3 19.2 24.7
F*+Mc 53533.1 53535.6 11.2 7.5
H+Mc 53695.2 53696.5 21.5 20.4
Mc+Mc 53986.5 53990.1 6.0 9.5
aCalculated from relative quantities of glycoforms Fc/2 (Table 1) assuming a random pairing.
bRelative ion intensities in transformed spectrum.
cIon peak not detected.
dRelative quantities of isomeric glycoforms E+H and F*+F* could be individually calculated from those of the other glycoforms of Fc and E,
F* and H of Fc/2.
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IgG and FcRn is 1:2, the pH dependence of the interaction
might be a¡ected by pairing of the sialyl oligosaccharides, e.g.
Mc+Mc, Mc+H and so on, resulting in a di¡erent e⁄ciency
of transport and catabolic half-life.
4. Concluding remarks
In the present paper, we have determined using nano ESI-
MS the glycoforms of IgG-Fc involving the paired oligosac-
charides in a quantitative way. It has been reported that parts
of IgG are asymmetrically glycosylated in the Fab and/or the
hinge regions [63^65]. Biological signi¢cances of the asymmet-
ric glycosylation in the Fab portion have been extensively
discussed [66]. The present nano ESI-MS data indicate that
the Fc portion can be asymmetric as well as symmetric from
the aspect of glycosylation. Since agalactosylation induces lo-
cal conformational change in Fc [67], asymmetric glycoforms
would result in asymmetric protein conformation of Fc. Since
IgG-Fc can be divalent and monovalent depending on its li-
gands [48,68^72], contribution to the biological activities of
the carbohydrate moiety in each of the heavy chains may be
cooperative as well as additive. Therefore, it is obviously nec-
essary to correlate the biological activities of IgG with direct
glycoforms of Fc as revealed in the present study rather than
simply with the overall compositions of liberated oligosaccha-
rides. We also propose that the nano ESI-MS-derived glyco-
sylation pro¢les of Fc are useful diagnostically and prognos-
tically, because they can be obtained with small amounts of
samples as compared to the chromatographic methods and
may o¡er insights into disease pathogenesis by providing
unique information of pairing of oligosaccharides. It has
been suggested that IgG exhibiting particular combinations
of the Fab- and Fc-associated glycoforms are preferentially
involved in self-association and aggregation and therefore
have pathological signi¢cance [73,74]. Current progress in
MS would make it possible in the near future to obtain quan-
titative information at a high resolution of carbohydrate het-
erogeneities of intact IgG molecule in which the Fab as well as
the Fc are glycosylated. Information on the Fc glycoforms
involving the paired oligosaccharides as determined in the
present study using the proteolytic fragments will contribute
to the basis of knowledge of complete glycoforms of the mul-
ti-glycosylated IgG molecules. The evaluation of pairing of
the oligosaccharides would be especially important for the
antibody engineering that intends to utilize the most e⁄ca-
cious Fc glycoform for a particular therapeutic purpose [75].
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